Rezolute (NASDAQ:RZLT) reported quarterly losses of $(0.26) per share which beat the analyst consensus estimate of $(0.32) by 18.75 percent. This is a 67.5 percent increase over losses of $(0.80) per share from the same period last year.
Reunion Neuroscience Announces $13.1M Take-Private Transaction With Biotech Investment Firm
As of May 31, clinical-stage psychedelics company Reunion Neuroscience Inc.